Enzo Biochem (ENZ) Tops Q1 EPS by 2c
Get Alerts ENZ Hot Sheet
Financial Fact:
Total operating expenses: 27.54M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Enzo Biochem (NYSE: ENZ) reported Q1 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.3 million versus the consensus estimate of $25.9 million.
On October 31, 2016, cash and cash equivalents totaled $67.2 million, and working capital was $69.7 million. Consolidated cash flows used in operation was only $334,000 in the current year quarter. With the retirement in December 2016 of our outstanding bank loan, the Company, apart from lease obligations, currently has no outstanding debt.
For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
- Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!